Xing Na, Long Xiao-Tong, Zhang Hui-Juan, Fu Li-Dan, Huang Jian-Yuan, Chaurembo Abdallah Iddy, Chanda Francis, Xu Yun-Jing, Shu Chi, Lin Kai-Xuan, Yang Ke, Lin Han-Bin
Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Front Pharmacol. 2022 Dec 6;13:1055248. doi: 10.3389/fphar.2022.1055248. eCollection 2022.
Ischemic heart disease (IHD) is a high-risk disease in the middle-aged and elderly population. The ischemic heart may be further damaged after reperfusion therapy with percutaneous coronary intervention (PCI) and other methods, namely, myocardial ischemia-reperfusion injury (MIRI), which further affects revascularization and hinders patient rehabilitation. Therefore, the investigation of new therapies against MIRI has drawn great global attention. Within the long history of the prevention and treatment of MIRI, traditional Chinese medicine (TCM) has increasingly been recognized by the scientific community for its multi-component and multi-target effects. These multi-target effects provide a conspicuous advantage to the anti-MIRI of TCM to overcome the shortcomings of single-component drugs, thereby pointing toward a novel avenue for the treatment of MIRI. However, very few reviews have summarized the currently available anti-MIRI of TCM. Therefore, a systematic data mining of TCM for protecting against MIRI will certainly accelerate the processes of drug discovery and help to identify safe candidates with synergistic formulations. The present review aims to describe TCM-based research in MIRI treatment through electronic retrieval of articles, patents, and ethnopharmacology documents. This review reported the progress of research on the active ingredients, efficacy, and underlying mechanism of anti-MIRI in TCM and TCM formulas, provided scientific support to the clinical use of TCM in the treatment of MIRI, and revealed the corresponding clinical significance and development prospects of TCM in treating MIRI.
缺血性心脏病(IHD)是中老年人群中的一种高危疾病。经皮冠状动脉介入治疗(PCI)等再灌注治疗后,缺血心脏可能会进一步受损,即心肌缺血再灌注损伤(MIRI),这进一步影响血管再通并阻碍患者康复。因此,针对MIRI的新疗法研究引起了全球广泛关注。在MIRI防治的漫长历史中,中医药因其多成分、多靶点作用日益受到科学界的认可。这些多靶点作用为中医药抗MIRI提供了显著优势,克服了单成分药物的缺点,从而为MIRI的治疗指明了一条新途径。然而,很少有综述总结目前可用的中医药抗MIRI研究。因此,对中医药防治MIRI进行系统的数据挖掘肯定会加速药物发现进程,并有助于识别具有协同配方的安全候选药物。本综述旨在通过电子检索文章、专利和民族药理学文献,描述基于中医药治疗MIRI的研究。本综述报道了中医药及中药复方抗MIRI活性成分、疗效及潜在机制的研究进展,为中医药治疗MIRI的临床应用提供科学支持,并揭示了中医药治疗MIRI的相应临床意义和发展前景。
Evid Based Complement Alternat Med. 2021-7-20
Zhongguo Zhong Yao Za Zhi. 2023-2
Pharmaceuticals (Basel). 2024-9-27
J Ethnopharmacol. 2023-1-30
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022-6
Evid Based Complement Alternat Med. 2022-6-6
Am J Physiol Cell Physiol. 2022-11-1
JACC Cardiovasc Interv. 2022-6-27